Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Related Clinical Trial
A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) CIDP07 Rozanolixizumab Post Trial Access Program (the PTA) Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Hizentra® in Inflammatory Neuropathies – pHeNIx Study Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC) InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy A Registered Cohort Study of Immune-Mediated Neuropathies Interest of Mycophenolate for CIDP Weaning Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Transcriptome Analysis of the Peripheral Blood in CIDP Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Subcutaneous Immunoglobulin for CIDP Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy MRI in Diagnosing and Monitoring CIDP High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Panzyga in CIDP Administered at Different Infusion Rates Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Brief Title

Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Official Title

NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Brief Summary

      Patients diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy were confirmed
      based on the European Federation of Neurological Societies/ Peripheral. Nerve Society
      Guideline. Patients who meet all inclusion criteria and do not conflict with the exclusion
      criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive
      days. Subsequently, patients receive NPB-01 1g/kg every 3weeks and evaluate the Inflammatory
      Neuropathy Cause and Treatment(INCAT) score and INCAT sensory sumscore(ISS) et al.

      As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse
      events by one year after the start of the study treatment.
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

proportion of patients with more than 1point improvement in the INCAT score relative to baseline at 28weeks.

Secondary Outcome

 INCAT score

Condition

Chronic Inflammatory Demyelinating Polyneuropathy

Intervention

NPB-01

Study Arms / Comparison Groups

 NPB-01
Description:  Intravenous immunoglobulin

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

49

Start Date

April 2013

Completion Date

September 2015

Primary Completion Date

September 2015

Eligibility Criteria

        Inclusion Criteria:

          -  1. Patients with progressive or relapsing motor and sensory dysfunction of more than
             one limb resulting from neuropathy within 2 months prior to the date informed consent
             is obtained.

          -  2. Patients who INCAT score between 2-9. (If the INCAT score is 1 in upper limb, the
             INCAT score of 2 must be exclusively from leg disability to qualify.)

          -  3. Patients who need high-dose intravenous immunoglobulin therapy.

          -  4. Patients who continued treatment for CIDP without addition or increase at 30 days
             before informed consent.

          -  5. Patients with greater than or equal to twenty years old at informed consent.

        Exclusion Criteria:

          -  1. Patients with evidence of myelopathy or demyelination of central nerve

          -  2. Patients with evidence of stroke, central nerve system trauma, or persistent
             neurological deficits due to peripheral neuropathy from other causes(diabetic
             neuropathy, IgM paraproteinaemia, uraemic neuropathy, toxic neuropathy, hereditary
             neuropathy)

          -  3. Patients with evidence of neuropathy or alcoholic neuropathy or vitamin deficiency
             neuropathy due to myeloma, lymphoma, sarcoidosis, systemic lupus erythematosus,
             malignancy, vasculitis, Crow-Fukase syndrome, Sjögren syndrome.

          -  4. Patients with multifocal motor neuropathy.

          -  5. Patients treated with plasmapheresis at 3 months before informed consent.

          -  6. Patients treated with rituximab at 6 months before informed consent.

          -  7. Patients treated with high-dose intravenous immunoglobulin(greater than or equal to
             1g/kg) at 8 weeks before informed consent.

          -  8. Patients treated with intravenous immunoglobulin at 3 weeks before informed
             consent.

          -  9. Patients with history of shock or hypersensitivity for NPB-01.

          -  10. Patients with IgA deficiency.

          -  11. Patients with malignancy at informed consent.

          -  12. Patients with impaired liver function.

          -  13. Patients with impaired renal function.

          -  14. Patients with cerebro- or cardiovascular disorders.

          -  15. Patients with high risk of thromboembolism.

          -  16. Patients with hemolytic/hemorrhagic anemia.

          -  17. Patients with decreased cardiac function.

          -  18. Patients with decreased platelet.
      

Gender

All

Ages

20 Years - 100 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Japan

Location Countries

Japan

Administrative Informations


NCT ID

NCT01824251

Organization ID

NPB-01-09/C-01


Responsible Party

Sponsor

Study Sponsor

Nihon Pharmaceutical Co., Ltd


Study Sponsor

, , 


Verification Date

October 2014